Aeglea Biotherapeutics (AGLE) Receives a Buy from Needham
In a report released today, Chad Messer from Needham reiterated a Buy rating on Aeglea Biotherapeutics (AGLE), with a price target of $14.00. The company’s shares closed last Wednesday at $5.20.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 4.4% and a 38.3% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aeglea Biotherapeutics with a $20.00 average price target, implying a 296.0% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.11 and a one-year low of $3.50. Currently, Aeglea Biotherapeutics has an average volume of 64.88K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.